Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Recurrence 1Pancreatic Neoplasms 1Neoplasm, Residual 1Leukemia, Myeloid, Acute 1Carcinoma, Renal Cell 1Advanced Solid Tumor 1

Interventions

Injections 24pembrolizumab 13toripalimab 12tislelizumab 9Gemcitabine 7Cisplatin 7Carboplatin 6atezolizumab 5Nivolumab 5Irinotecan 5Pemetrexed 4Oxaliplatin 4Leucovorin 4Fluorouracil 4Docetaxel 4Cetuximab 4trastuzumab deruxtecan 3spartalizumab 3cediranib 3Paclitaxel 3PM 01183 3Capecitabine 3sintilimab 2olaparib 2lenvatinib 2glumetinib 2camrelizumab 2apatinib 2Therapeutics 2Midazolam 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Solid Tumor × CD3 Complex × Clear all
NCT07408258 2026-04-13

Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors

OncoC4, Inc.

Phase 1 Not yet recruiting
20 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡